medullary thyroid cancer semaglutide What is the truth about GLP one agonist and cancer? There is currently a warning for GLP1 Agnes like Ozempic Wegovy, Zepbound and Mounjaro for potential increased risk of thyroid Semaglutide (Ozempic) carries FDA warnings

Predictable Access Without Plan Shock Weight Health HRA HSA and FSA Education Global LSA See Your Savings Clearly GLP-1 Strategy In Our Words GLP-1 Demand is Here: How Employers Can Offer Access Without Driving Up Costs Access Webinar HRA and LSA Legal Considerations for GLP-1 Coverage Download Compliance Flyer Tame GLP-1 Costs Read Blog Rethinking Cost Control Read Editorial Sources: (1) Nutrition & Diabetes Journal, 2024

chronic diabetic ketoacidosis

Weight-focused users tend to stay on the drugs for shorter periods of time, with only 44% continuing to use them after one year, compared with nearly 70% of those using the medications for other health conditions

Both semaglutide and tirzepatide have been on FDA shortage lists intermittently since 2022, making compounded versions legally available and clinically appropriate